QuidelOrtho Corporation (QDEL) AI Stock Analysis

QuidelOrtho Corporation develops and manufactures diagnostic testing technologies for healthcare providers across four core business units. The Labs segment supplies clinical chemistry and immunoassay instruments and assays that measure chemicals and proteins in bodily fluids to monitor disease and guide therapeutic care. Transfusion Medicine delivers immunohematology instruments and donor screening assays for blood typing, recipient compatibility, and infectious disease detection. The Point-of-Care unit provides rapid diagnostic tests delivering swift results in clinical settings outside central laboratories. Molecular Diagnostics offers polymerase chain reaction thermocyclers, analyzers, and amplification systems for detecting genetic material.

QuidelOrtho generated $2.73B in revenue in FY2025, marking consecutive annual contractions following $3.00B in FY2023 and $2.78B in FY2024 after a peak of $3.27B in FY2022. Gross margin narrowed from 75.3% in FY2021 to 46.7% in FY2025, while operating margin fell to -33.7%. Net income remained negative at -$1.13B in FY2025, following a net loss of -$2.05B in FY2024. Over the trailing twelve months, revenue reached $2.67B with an operating margin of -2.1% and a profit margin of -39.2%. In the latest quarter ended June 30, 2026, quarterly revenue grew 2.8% year-over-year, while quarterly earnings declined 77.1%.

As of June 30, 2026, QuidelOrtho held $123.4M in cash and short-term investments alongside $3.08B in total debt, leaving net debt at $2.95B. Total assets stood at $5.72B against shareholders' equity of $1.77B, resulting in a debt-to-equity ratio of 1.73 and a current ratio of 1.39. Operating cash flow totaled $105.2M in FY2025, but capital expenditures of $188.2M drove free cash flow to -$83.0M. Over the past five years, the company's share count increased 60.7%.

QuidelOrtho trades at a forward P/E of 9.6x, below the 17.3x median of its US-listed Healthcare peers. Its price-to-sales ratio of 0.3x and price-to-book ratio of 0.4x both trade below peer medians of 4.1x and the sector averages. However, its EV/EBITDA multiple of 22.8x sits above the peer median of 12.0x, reflecting an enterprise value of $3.66B relative to a market capitalization of $885.3M. Over the past year, the stock fell 54.6%, trailing the S&P 500 return of 16.8%, and stands 89.9% lower over five years compared to an 83.0% gain for the benchmark.

Wall Street coverage includes 1 Strong Buy, 1 Hold, and 1 Sell recommendation. The mean price target is $14.67, representing a 13.6% premium over the last close of $12.91. For the current fiscal year ending December 31, 2026, consensus estimates project revenue of $2.54B and EPS of $0.77, representing a 63.5% earnings contraction. For the next fiscal year, two analysts project revenue of $2.59B and EPS of $1.43. QuidelOrtho exceeded EPS estimates in 3 of the last 4 quarters, with its next earnings release scheduled for November 4, 2026.

This page is an AI-written research summary of QuidelOrtho Corporation (QDEL). The text was generated on October 30, 2026 from Quotelinks data as of October 16, 2026 (company profile, annual results, latest balance sheet, valuation, price performance and analyst estimates). An automatic check rejects any draft that contains a figure not found in that data. It is not investment advice; verify figures on the linked tabs before making decisions.

Related: QDEL income statement, QDEL balance sheet, QDEL key metrics, QDEL analyst forecast, QDEL chart. See the QDEL stock overview for the latest quote and news.